Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 3Leukemia 2Burkitt Lymphoma 2Recurrence 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Bites and Stings 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrence × blinatumomab × Clear all
NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡